ABROCITINIB (Cibinqo ®)

Clinical Indication

treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy

Comments

Not yet reviewed

Date of classification

October 2021

Review date

October 2021

Black

Drugs not recommended for use in the Leicestershire Health Community because of lack of evidence of clinical effectiveness, cost prioritization or concerns over safety.

All new drugs will be black until they have been through the appropriate approval process - then they will appear as a specific entry.